{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:44:18Z","timestamp":1789879458397,"version":"4.0.1"},"reference-count":70,"publisher":"Elsevier BV","issue":"5-6","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cytokine & Growth Factor Reviews"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1016\/j.cytogfr.2007.06.020","type":"journal-article","created":{"date-parts":[[2007,8,11]],"date-time":"2007-08-11T11:09:33Z","timestamp":1186830573000},"page":"451-458","source":"Crossref","is-referenced-by-count":25,"title":["Present role and future potential of type I interferons in adjuvant therapy of high-risk operable melanoma"],"prefix":"10.1016","volume":"18","author":[{"given":"Stergios","family":"Moschos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Kirkwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.cytogfr.2007.06.020_bib1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nri2038","article-title":"Cooperation of Toll-like receptor signals in innate immune defence","volume":"7","author":"Trinchieri","year":"2007","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"10.1016\/j.cytogfr.2007.06.020_bib2","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/ni1243","article-title":"IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction","volume":"6","author":"Kawai","year":"2005","journal-title":"Nat Immunol"},{"issue":"5421","key":"10.1016\/j.cytogfr.2007.06.020_bib3","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1126\/science.284.5421.1835","article-title":"The nature of the principal type 1 interferon-producing cells in human blood","volume":"284","author":"Siegal","year":"1999","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.cytogfr.2007.06.020_bib4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nm1352","article-title":"Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity","volume":"12","author":"Chan","year":"2006","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.cytogfr.2007.06.020_bib5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/path.1344","article-title":"Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas","volume":"200","author":"Vermi","year":"2003","journal-title":"J Pathol"},{"issue":"12","key":"10.1016\/j.cytogfr.2007.06.020_bib6","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/nm1201-1339","article-title":"Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells","volume":"7","author":"Zou","year":"2001","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.cytogfr.2007.06.020_bib7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1073\/pnas.63.1.51","article-title":"Increased survival in mice inoculated with tumor cells and treated with interferon preparations","volume":"63","author":"Gresser","year":"1969","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.cytogfr.2007.06.020_bib8","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1073\/pnas.78.2.1171","article-title":"Influence of anti-mouse interferon serum on the growth and metastasis of tumor cells persistently infected with virus and of human prostatic tumors in athymic nude mice","volume":"78","author":"Reid","year":"1981","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"10.1016\/j.cytogfr.2007.06.020_bib9","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ni1213","article-title":"A critical function for type I interferons in cancer immunoediting","volume":"6","author":"Dunn","year":"2005","journal-title":"Nat Immunol"},{"issue":"7","key":"10.1016\/j.cytogfr.2007.06.020_bib10","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa053007","article-title":"Prognostic significance of autoimmunity during treatment of melanoma with interferon","volume":"354","author":"Gogas","year":"2006","journal-title":"N Engl J Med"},{"issue":"35","key":"10.1016\/j.cytogfr.2007.06.020_bib11","doi-asserted-by":"crossref","first-page":"8968","DOI":"10.1200\/JCO.2005.01.109","article-title":"Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206","volume":"23","author":"Ribas","year":"2005","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.cytogfr.2007.06.020_bib12","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJM198806163182401","article-title":"Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells","volume":"318","author":"Atkins","year":"1988","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.cytogfr.2007.06.020_bib13","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nm1590","article-title":"TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity","volume":"13","author":"Baccala","year":"2007","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.cytogfr.2007.06.020_bib14","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1067\/mjd.2002.126215","article-title":"Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study","volume":"47","author":"Geisse","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.cytogfr.2007.06.020_bib15","doi-asserted-by":"crossref","unstructured":"Leichman G, et al. CPG 7909, a TLR9 Agonist, added to first line taxane\/platinum for advanced non-small cell lung cancer, A Randomized, Controlled Phase II Study (Abstr 7039) in ASCO Annual Meeting Proceedings, vol. 23; 2005.","DOI":"10.1200\/jco.2005.23.16_suppl.7039"},{"issue":"5","key":"10.1016\/j.cytogfr.2007.06.020_bib16","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/cncr.10775","article-title":"Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690","volume":"95","author":"Kirkwood","year":"2002","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.cytogfr.2007.06.020_bib17","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1158\/1078-0432.CCR-06-1387","article-title":"Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b","volume":"13","author":"Wang","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.cytogfr.2007.06.020_bib18","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/ni829","article-title":"DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL","volume":"3","author":"Litinskiy","year":"2002","journal-title":"Nat Immunol"},{"issue":"5","key":"10.1016\/j.cytogfr.2007.06.020_bib19","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.cytogfr.2007.06.020_bib20","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1089\/10799900252952280","article-title":"Mechanisms for regulation of cellular responsiveness to human IFN-beta1a","volume":"22","author":"Dupont","year":"2002","journal-title":"J Interferon Cytokine Res"},{"issue":"52","key":"10.1016\/j.cytogfr.2007.06.020_bib21","doi-asserted-by":"crossref","first-page":"35056","DOI":"10.1074\/jbc.273.52.35056","article-title":"The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities","volume":"273","author":"Song","year":"1998","journal-title":"J Biol Chem"},{"issue":"16","key":"10.1016\/j.cytogfr.2007.06.020_bib22","doi-asserted-by":"crossref","first-page":"5662","DOI":"10.1128\/MCB.22.16.5662-5668.2002","article-title":"Identification of a nuclear Stat1 protein tyrosine phosphatase","volume":"22","author":"ten Hoeve","year":"2002","journal-title":"Mol Cell Biol"},{"issue":"9","key":"10.1016\/j.cytogfr.2007.06.020_bib23","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/ni1104","article-title":"PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity","volume":"5","author":"Liu","year":"2004","journal-title":"Nat Immunol"},{"issue":"11","key":"10.1016\/j.cytogfr.2007.06.020_bib24","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1182\/blood.V97.11.3568","article-title":"Expression of interferon-alpha (IFN-alpha) receptor 2c at diagnosis is associated with cytogenetic response in IFN-alpha-treated chronic myeloid leukemia","volume":"97","author":"Barthe","year":"2001","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cytogfr.2007.06.020_bib25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ijc.20236","article-title":"Interferon receptor expression regulates the antiproliferative effects of interferons on cancer cells and solid tumors","volume":"111","author":"Wagner","year":"2004","journal-title":"Int J Cancer"},{"issue":"17","key":"10.1016\/j.cytogfr.2007.06.020_bib26","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/jnci\/djh252","article-title":"Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy","volume":"96","author":"Lesinski","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.cytogfr.2007.06.020_bib27","doi-asserted-by":"crossref","first-page":"pe176","DOI":"10.1371\/journal.pmed.0040176","article-title":"Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma","volume":"4","author":"Critchley-Thorne","year":"2007","journal-title":"PLoS Med"},{"issue":"9","key":"10.1016\/j.cytogfr.2007.06.020_bib28","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00262-004-0649-y","article-title":"Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy","volume":"54","author":"Lesinski","year":"2005","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.cytogfr.2007.06.020_bib29","first-page":"42","article-title":"The suppressor of cytokine signaling-1 is constitutively expressed in chronic myeloid leukemia and correlates with poor cytogenetic response to interferon-alpha","volume":"89","author":"Roman-Gomez","year":"2004","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.cytogfr.2007.06.020_bib30","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1182\/blood-2002-01-0073","article-title":"Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells","volume":"100","author":"Sakai","year":"2002","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.cytogfr.2007.06.020_bib31","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.4049\/jimmunol.178.8.4832","article-title":"IFN-alpha-induced signal transduction, gene expression, and antitumor activity of immune effector cells are negatively regulated by suppressor of cytokine signaling proteins","volume":"178","author":"Zimmerer","year":"2007","journal-title":"J Immunol"},{"issue":"6948","key":"10.1016\/j.cytogfr.2007.06.020_bib32","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nature01850","article-title":"Integration of interferon-alpha\/beta signalling to p53 responses in tumour suppression and antiviral defence","volume":"424","author":"Takaoka","year":"2003","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.cytogfr.2007.06.020_bib33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1600-0609.1997.tb00965.x","article-title":"How does interferon exert its cell growth inhibitory effect?","volume":"59","author":"Grander","year":"1997","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.cytogfr.2007.06.020_bib34","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1006\/abbi.1996.0078","article-title":"Effect of interferon on protein translation during growth stages of 3T3 cells","volume":"326","author":"Petryshyn","year":"1996","journal-title":"Arch Biochem Biophys"},{"issue":"12","key":"10.1016\/j.cytogfr.2007.06.020_bib35","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1089\/jir.2005.25.799","article-title":"Alternative signaling pathways regulating type I interferon-induced apoptosis","volume":"25","author":"Pokrovskaja","year":"2005","journal-title":"J Interferon Cytokine Res"},{"issue":"22","key":"10.1016\/j.cytogfr.2007.06.020_bib36","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199205283262203","article-title":"Interferon alfa-2a therapy for life-threatening hemangiomas of infancy","volume":"326","author":"Ezekowitz","year":"1992","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.cytogfr.2007.06.020_bib37","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/jnci\/95.6.437","article-title":"Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis","volume":"95","author":"von Marschall","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.cytogfr.2007.06.020_bib38","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1073\/pnas.92.10.4562","article-title":"Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas","volume":"92","author":"Singh","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"10.1016\/j.cytogfr.2007.06.020_bib39","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2174\/1381612033391423","article-title":"Regulation of angiogenesis by Th1- and Th2-type cytokines","volume":"9","author":"Naldini","year":"2003","journal-title":"Curr Pharm Des"},{"issue":"8","key":"10.1016\/j.cytogfr.2007.06.020_bib40","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1158\/1078-0432.CCR-06-1805","article-title":"Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b","volume":"13","author":"Yurkovetsky","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.cytogfr.2007.06.020_bib41","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/CMR.0b013e3281ad91a3","article-title":"Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents","volume":"17","author":"Moschos","year":"2007","journal-title":"Melanoma Res"},{"key":"10.1016\/j.cytogfr.2007.06.020_bib42","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1600-065X.2006.00442.x","article-title":"Immune resistance orchestrated by the tumor microenvironment","volume":"213","author":"Gajewski","year":"2006","journal-title":"Immunol Rev"},{"issue":"4","key":"10.1016\/j.cytogfr.2007.06.020_bib43","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1470-2045(04)01429-9","article-title":"Adjuvant interferon alfa treatment for patients with malignant melanoma stimulates transporter proteins associated with antigen processing and proteasome activator 28","volume":"5","author":"Abuzahra","year":"2004","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.cytogfr.2007.06.020_bib44","doi-asserted-by":"crossref","first-page":"5934","DOI":"10.1158\/0008-5472.CAN-04-1261","article-title":"Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimizedCTL-inducing activity","volume":"64","author":"Mailliard","year":"2004","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.cytogfr.2007.06.020_bib45","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/1042819031000149368","article-title":"Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation","volume":"45","author":"Tough","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"19","key":"10.1016\/j.cytogfr.2007.06.020_bib46","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1200\/JCO.2005.05.2498","article-title":"Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses","volume":"24","author":"Moschos","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cytogfr.2007.06.020_bib47","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/0-387-24361-5_9","article-title":"Interferons in the treatment of solid tumors","volume":"126","author":"Moschos","year":"2005","journal-title":"Cancer Treat Res"},{"issue":"1","key":"10.1016\/j.cytogfr.2007.06.020_bib48","doi-asserted-by":"crossref","first-page":"32","DOI":"10.7326\/0003-4819-103-1-32","article-title":"Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers","volume":"103","author":"Kirkwood","year":"1985","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.cytogfr.2007.06.020_bib49","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.cytogfr.2007.06.020_bib50","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1200\/JCO.1996.14.10.2666","article-title":"Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study","volume":"14","author":"Cole","year":"1996","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.cytogfr.2007.06.020_bib51","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1200\/JCO.1997.15.6.2351","article-title":"Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684","volume":"15","author":"Hillner","year":"1997","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.cytogfr.2007.06.020_bib52","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1200\/JCO.2000.18.12.2444","article-title":"High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690\/S9111\/C9190","volume":"18","author":"Kirkwood","year":"2000","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.cytogfr.2007.06.020_bib53","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1200\/JCO.1994.12.5.1036","article-title":"Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside.","volume":"12","author":"Livingston","year":"1994","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.cytogfr.2007.06.020_bib54","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1200\/JCO.2001.19.9.2370","article-title":"High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH\/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694\/S9512\/C509801","volume":"19","author":"Kirkwood","year":"2001","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.cytogfr.2007.06.020_bib55","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ejca.2003.07.004","article-title":"Final results of the EORTC 18871\/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3mm) or regional lymph node metastasis","volume":"40","author":"Kleeberg","year":"2004","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.cytogfr.2007.06.020_bib56","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1054\/bjoc.2000.1623","article-title":"Adjuvant interferon alpha 2b in high risk melanoma\u2014the Scottish study","volume":"84","author":"Cameron","year":"2001","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.cytogfr.2007.06.020_bib57","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1200\/JCO.1998.16.4.1425","article-title":"Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group","volume":"16","author":"Pehamberger","year":"1998","journal-title":"J Clin Oncol"},{"issue":"9120","key":"10.1016\/j.cytogfr.2007.06.020_bib58","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(97)12445-X","article-title":"Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5mm without clinically detectable node metastases. French Cooperative Group on Melanoma","volume":"351","author":"Grob","year":"1998","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cytogfr.2007.06.020_bib59","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1200\/JCO.2004.03.185","article-title":"Adjuvant interferon in high-risk melanoma: the AIM HIGH Study, United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma","volume":"22","author":"Hancock","year":"2004","journal-title":"J Clin Oncol"},{"issue":"9285","key":"10.1016\/j.cytogfr.2007.06.020_bib60","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0140-6736(01)06068-8","article-title":"Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial","volume":"358","author":"Cascinelli","year":"2001","journal-title":"Lancet"},{"issue":"9492","key":"10.1016\/j.cytogfr.2007.06.020_bib61","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0140-6736(05)67482-X","article-title":"Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb\/III melanoma (EORTC 18952): randomised controlled trial","volume":"366","author":"Eggermont","year":"2005","journal-title":"Lancet"},{"issue":"8902","key":"10.1016\/j.cytogfr.2007.06.020_bib62","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0140-6736(94)90030-2","article-title":"Results of adjuvant interferon study in WHO melanoma programme","volume":"343","author":"Cascinelli","year":"1994","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.cytogfr.2007.06.020_bib63","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1158\/1078-0432.CCR-1103-3","article-title":"A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma","volume":"10","author":"Kirkwood","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.cytogfr.2007.06.020_bib64","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0305-7372(03)00074-4","article-title":"Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials","volume":"29","author":"Wheatley","year":"2003","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"10.1016\/j.cytogfr.2007.06.020_bib65","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/cncr.21760","article-title":"Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma","volume":"106","author":"Verma","year":"2006","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.cytogfr.2007.06.020_bib66","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa061592","article-title":"NALP1 in vitiligo-associated multiple autoimmune disease","volume":"356","author":"Jin","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cytogfr.2007.06.020_bib67","series-title":"International Society for Biological Therapy of Cancer, 19th Annual Meeting","article-title":"Melanoma gene expression profiles to identify mechanisms of tumor resistance to a multi-peptide\/IL-12 vaccine (oral presentation)","author":"Harlin","year":"2004"},{"issue":"2","key":"10.1016\/j.cytogfr.2007.06.020_bib68","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1172\/JCI16603","article-title":"The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse","volume":"112","author":"Lesinski","year":"2003","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.cytogfr.2007.06.020_bib69","first-page":"4347","article-title":"Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: implications for cancer vaccines","volume":"9","author":"Astsaturov","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cytogfr.2007.06.020_bib70","first-page":"13","article-title":"Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871","volume":"2","author":"Liu","year":"2002","journal-title":"Cancer Immunol"}],"container-title":["Cytokine & Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610107000895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610107000895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T23:17:29Z","timestamp":1556752649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610107000895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":70,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S1359610107000895"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2007.06.020","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}